Flexion has assembled a pipeline of novel pharmaceuticals and developed delivery systems that enable local, sustained release of these drugs at the locus of disease. Flexion has initially focused on osteoarthritis (OA), a disease of epidemic proportions. The three candidates in Flexion's portfolio, FX005, FX006 and FX007 represent three distinct pharmacologies. FX005 is a p38 inhibitor that combines both analgesic and anti-inflammatory properties; FX006 is a corticosteroid that acts primarily as an anti-inflammatory; and FX007 is a TrkA inhibitor that is primarily an analgesic. In the animations below, the molecular/cellular bases for the activity of FX006 and FX007, specifically in the context of osteoarthritis, are characterized. Together, these products have the potential to treat mild, moderate and severe forms of the disease and to slow disease progression.
